Press release

27 Feb 2025  ·  Regulatory information

Guard Therapeutics announces positive outcome from first independent safety data review in Phase 2b POINTER study

Guard Therapeutics announced today that an independent Data Safety Monitoring Committee (DSMC) has completed its first planned review of safety data and has recommended that the Phase 2b clinical study POINTER continue as planned. The committee reviewed safety data from 67 patients, corresponding to more than one-third of the planned number of patients in the study, which evaluates the drug candidate RMC-035 as a kidney protective treatment in open-heart surgery.

“We are very pleased with the committee’s recommendation. Patient recruitment for the study will now continue according to the existing study protocol, and in the second quarter of 2025, we expect to present the results of the next safety review, which will include data from about two-thirds of the total planned patients,” said Guard Therapeutics’ CEO, Tobias Agervald. “Meanwhile, recruitment is progressing very well, and we have now enrolled half of the planned number of patients in the study.”

Patient recruitment is expected to be completed in Q3 2025, with the overall study results anticipated approximately six months after recruitment is finalized.

All press releases